191 related articles for article (PubMed ID: 22520146)
21. Medical therapy for non-functioning pituitary tumors-a critical approach.
Tampourlou M; Karapanou O; Vassiliadi DA; Tsagarakis S
Hormones (Athens); 2019 Jun; 18(2):117-126. PubMed ID: 30368687
[TBL] [Abstract][Full Text] [Related]
22. Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
Iglesias P; Díez JJ
Am J Med; 2011 Jun; 124(6):e3-4. PubMed ID: 21605718
[No Abstract] [Full Text] [Related]
23. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).
Gaztambide S; Vazquez F; Castaño L
Minerva Endocrinol; 2013 Mar; 38(1):17-28. PubMed ID: 23435440
[TBL] [Abstract][Full Text] [Related]
24. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
27. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
28. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.
Touma W; Hoostal S; Peterson RA; Wiernik A; SantaCruz KS; Lou E
J Clin Neurosci; 2017 Jul; 41():75-77. PubMed ID: 28291643
[TBL] [Abstract][Full Text] [Related]
31. Management of aggressive pituitary adenomas: current treatment strategies.
Buchfelder M
Pituitary; 2009; 12(3):256-60. PubMed ID: 19003540
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
34. Hyperprolactinaemia.
Prabhakar VK; Davis JR
Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):341-53. PubMed ID: 17889620
[TBL] [Abstract][Full Text] [Related]
35. Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.
Mercado M; Melgar V; Salame L; Cuenca D
Endocrinol Diabetes Nutr; 2017; 64(7):384-395. PubMed ID: 28745610
[TBL] [Abstract][Full Text] [Related]
36. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
[TBL] [Abstract][Full Text] [Related]
37. Parathyroid carcinoma in a patient with non-secretory pituitary tumor: a variant of multiple endocrine neoplasia type-I?
Wu CW; Huang CI; Tsai ST; Chiang H; Lui WY; P'eng FK
Eur J Surg Oncol; 1992 Oct; 18(5):517-20. PubMed ID: 1358678
[TBL] [Abstract][Full Text] [Related]
38. Multiple endocrine neoplasia type 1: from bedside to benchside.
Yoshimoto K
J Med Invest; 2000 Aug; 47(3-4):108-17. PubMed ID: 11019489
[TBL] [Abstract][Full Text] [Related]
39. Prolactinoma surgery.
Jan M; Dufour H; Brue T; Jaquet P
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
[TBL] [Abstract][Full Text] [Related]
40. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
